Stocks of all sizes enjoyed another prosperous week, with the FTSE 100 blue-chip index setting a new record by breaking past the 8,200 mark for the first time on Friday.
In the U.S., Apple delivered a robust performance in its second quarter, which was unexpectedly strong, and announced a massive $110 billion buyback, boosting blue-chip stocks on Friday.
Meanwhile, the AIM index achieved a 10-month high, rising 1.8% to 770.
What happens when your company’s share price reaches a record high? It appears that cashing out is the strategy, as demonstrated by executives at AIM-listed cosmetics supplier Warpaint London. Reports on Friday indicated that CEO Samuel Bazini and Managing Director Eoin Macleod sold shares totalling £31.5 million at 450p each, which accounts for more than 9% of the company’s issued share capital.
Warpaint explained that this share sale was “in response to strong investor demand following the release of the company’s full-year results, and to enhance the company’s free float and expand its shareholder base.”
The offering was originally set to consist of six million shares but was increased due to this robust investor interest. As a non-dilutive bookbuild, the share sale had a limited impact on Warpaint’s stock price, which was down approximately 5% by the start of Friday.
Electric Guitar PLC (AIM: ELEG) celebrated its AIM debut on Friday, following the acquisition of first-party data specialist 3radical and a successful £1.32 million fundraising effort. 3radical has developed a software-as-a-service platform called Voco, which allows organizations to interactively engage individuals and directly request their data at scale.
John Regan, CEO of Electric Guitar, remarked, “Today is a significant milestone as our shares begin trading on AIM. This move underlines our belief in the future growth prospects.” The company’s shares rose by 1.25% to 2.02p after the listing.
In another development, The Works transitioned from the main market to AIM, which Chair Carolyn Bradley described as a better-suited platform due to the rising costs and regulatory demands of the main market.
This week also highlighted shifts in the energy sector. Europa Oil & Gas expressed a preference for operations in Equatorial Guinea over the British North Sea, criticizing the UK regulator’s approach to North Sea licensing. The company was displeased with the North Sea Transition Authority’s attempts to force a partnership with another firm, leading to a 7% drop in their share price throughout the week.
Similarly, Deltic Energy lamented the politicization of the North Sea, which it claimed severely hampered the long-term investment capabilities of UK Exploration and Production companies. CEO Graham Swindells emphasized the difficulties in advancing the Pensacola project, a significant recent discovery, due to political interference. As a result, Deltic faced tougher fundraising conditions and saw its shares halve in value.
In the mining sector, Asiamet Resources led with a 36% increase, following optimistic analysis from Optiva Securities, which argued that the company’s shares were undervalued due to project delays and fluctuating investor sentiment. Despite this rally, Asiamet’s shares at 1.15p remain far from Optiva’s risked net asset valuation of 7.22p per share.
Trinity Exploration & Production surged 47% after agreeing to an all-share acquisition by Touchstone Exploration Inc worth £24.1 million.
In biotech, Ondine Biomedical Inc saw a 27% rise in its shares on Friday following the announcement of a £3 million equity round that included a substantial premium to the prior day’s closing price. The funds will support the growth of its Steriwave nasal decolonization therapy.
Another notable mover in biotech was Angle plc, whose shares increased by 20% after it announced a supplier agreement with AstraZeneca to develop a detection assay for prostate cancer studies, valued at £550,000 and due for completion in the next year.
